We used fold change of NKILA (tumor/matched normal tissues) as the expression level of each patient and found that 54.01% of ESCC patients showed decreased expression (Fold change < 1) of NKILA (Fig. 1C). The gene discussed is NKILA; the disease is neoplasm.